Development of an enzyme immunoassay for a stable amidated analog of the hemoregulatory peptide Acetyl-Ser-Asp-Lys-Pro

Journal of Immunoassay and Immunochemistry

Volumn 22, Issue 1, 2001, Pages 15-31

  Junot, Christophe ^a,b   Theodoro, Frederic ^a,b   Thierry, Josiane ^a,b   Clement, Gilles ^a,b   Wdzieczak Bakala, Johanna ^a,b   Ezan, Eric ^a,b  

^a INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES   (France)

^b DIF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ANTINEOPLASTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SERASPENIDE; TETRAPEPTIDE;

AMIDATION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL PROTECTION; CHEMICAL STRUCTURE; CONTROLLED STUDY; CROSS REACTION; ENZYME IMMUNOASSAY; HEMATOPOIETIC STEM CELL; MASS SPECTROMETRY; MOUSE; NONHUMAN; SENSITIVITY AND SPECIFICITY;

AMIDES; ANIMALS; HUMANS; IMMUNE SERA; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED CBA; OLIGOPEPTIDES; PROTEIN CONFORMATION; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 0034907697     PISSN: 15321819     EISSN: None     Source Type: Journal    
DOI: 10.1081/IAS-100102895     Document Type: Article

References (24)

1. Inhibitor of hematopoietic pluripotent stem cell proliferation: Purification and determination of its structure
2. Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP
3. + subpopulation in response to growth factors
4. Activity of Acetyl-Ser-Asp-Lys-Pro (AcSDKP) on hematopoietic progenitors in short-term and long-term murine bone marrow cultures
5. Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy enhancing the myelopoietic response to GM-CSF
6. The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (goralatide) protects mice from doxorubicine-induced toxicity: Improvement in mice survival and protection of bone marrow stem cells and progenitors
7. In vivo protective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation
8. In vivo radioprotective effect of AcSDKP on canine myelopoiesis
9. Seraspenide (AcSDKP): Etude en phase I-II d'un inhibiteur de hematopiese protegeant de la toxicite de monochimiotherapies aracytine et ifosfamide
10. Involvement of human plasma Angiotensin I-Converting Enzyme in the degradation of the haemoregulatory peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline
11. Acute angiotensin-converting enzyme inhibition increases the plasma levels of the natural stem cell regulator N-Acetyl-Seryl-Aspartyl-Lysyl-Proline
12. Pharmacokinetics in healthy volunteers and patients of N-AcSDKP (seraspenide), a negative regulator of hematopoiesis
13. NAcSDKP analogues resistant to angiotensin-converting enzyme
14. In vitro effect of Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) analogs resistant to Angiotensin I-Converting Enzyme on hematopoietic stem cells and progenitor cell proliferation
15. Validation of immunoassays for bioanalysis: A pharmaceutical industry perspective
16. Distribution of a negative regulator of haemopoietic stem cell proliferation (AcSDKP) and thymosin beta 4 in mouse tissues
17. Acylalkylcarbonates as acylating agents for the synthesis of peptides
18. Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analyzed by enzyme immunoassay
19. Effect of Angiotensin-Converting Enzyme inhibition on plasma, urine and tissue concentrations of the hemoregulatory peptide Acetyl-Ser-Asp-Lys-Pro in rats
20. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modelling. Residual tissue blood. 1. Theoretical considerations
21. Inhibitory peptides in hematopolesis
22. Renal and metabolic clearance of AcSDKP during ACE inhibition in humans
23. Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoiesic stem cells by hematopoietic microenvironmental cells